Troutman Pepper advised Viridian Therapeutics on the deal. Viridian Therapeutics, In announced that it had issued shares in an underwritten public offering resulting in Viridian receiving approximately...
You must be a Standard 1 Year member to access this content.
Troutman Pepper advised Botanix Pharmaceuticals Limited on the deal. Botanix Pharmaceuticals Limited (ASX: BOT), a clinical dermatology company, has announced the acquisition of Sofpironium Bromide gel,...
You must be a Standard 1 Year member to access this content.
Troutman Pepper advised Trevena on the deal. Trevena, a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system...
You must be a Standard 1 Year member to access this content.
Troutman Pepper advised Seismic Therapeutic, Inc. on the deal while Gunderson Dettmer represented Lightspeed Venture Partners. Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for...
You must be a Standard 1 Year member to access this content.
Simpson Thacher represented SK Group on the deal while Troutman Pepper Hamilton Sanders advised Center for Breakthrough Medicines. SK Inc. announced its $350 million investment in The...
You must be a Standard 1 Year member to access this content.
Troutman Pepper Hamilton Sanders advised Context Therapeutics Inc. on the deal. Context Therapeutics Inc., a women’s oncology company developing advanced small molecule and immunotherapy treatments to...
You must be a Standard 1 Year member to access this content.
Troutman Pepper Hamilton Sanders LLP advised Pandion Therapeutics, Inc. on the deal.Pandion Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapeutics for those living with autoimmune...
You must be a Standard 1 Year member to access this content.
